Divi’s Laboratories Ltd., integrated in 1990, is a big capitalized corporate (with a marketplace capitalization of Rs 87,753.29 crore) working within the pharmaceutical sector.
Key product/earnings segments of Divi’s Laboratories Ltd. contains prescribed drugs, scrap, export incentives and contract charges for the yr ended 31 March 2022.
For the quarter ended September 30, 2022, the corporate reported a consolidated overall source of revenue of Rs 1,934.62 crore, down 17.43% from the former quarter. crore. The corporate reported an after-tax web benefit of Rs 493.60 crore in the most recent quarter.
Promoter / FII Holdings
As of September 30, 2022, the promoters owned 51.94% of the corporate’s stocks, FII – 22.1%, DII – 20.64%.
(Disclaimer: The suggestions on this segment, or any experiences connected to it, are ready by way of a 3rd birthday party. Critiques expressed are the ones of the respective authors/organizations. They don’t constitute the perspectives of the Financial Instances (ET). ET does now not ensure, warrants for, endorses any of its contents and hereby disclaims all warranties, specific or implied, in the case of the similar. Please seek the advice of your monetary consultant and search impartial recommendation.